Overview

Study of S 95005 in Combination With Oxaliplatin in Metastatic Colorectal Cancer

Status:
Completed
Trial end date:
2020-04-09
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to assess the safety and tolerability and to determine the recommended phase 2 dose of S 95005 given in combination with oxaliplatin in patients with metastatic colorectal cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Institut de Recherches Internationales Servier
Collaborator:
ADIR, a Servier Group company
Treatments:
Bevacizumab
Nivolumab
Oxaliplatin
Trifluridine